Drugs / GSK2241658A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01213472 | Jan 2011 → Apr 2018 | melanoma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2241658A | “Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma” NCT01213472 ↗ |
| Known as | 2241658A | “GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)” NCT01213472 ↗ |
| Route | Intramuscular | “Up to 24 intramuscular administrations” NCT01213472 ↗ |